background
respiratori
tract
infect
widespread
may
caus
signific
morbid
mortal
immunosuppress
popul
oncolog
patient
object
realaccur
respiratori
rt
pcr
kit
cover
respiratori
virus
compar
respifind
broadspectrum
multiplex
ligationdepend
probe
amplif
mlpa
test
target
viral
bacteri
respiratori
pathogen
studi
design
verif
analyt
perform
clinic
perform
respifind
evalu
reanalysi
respiratori
sampl
oncolog
patient
addit
time
result
ttr
method
compar
result
analyt
perform
respifind
fulfil
previous
specifi
criteria
concord
result
assay
achiev
clinic
specimen
posit
result
taken
account
respifind
yield
addit
result
total
sampl
due
higher
test
sensit
broader
highli
multiplex
spectrum
pathogen
ttr
typic
routin
test
consist
three
sampl
min
realaccur
respiratori
rt
pcr
kit
respifind
respect
howev
handson
time
reduc
appli
mlpa
method
conclus
hand
respifind
show
excel
analyt
perform
handson
time
halv
comparison
rt
pcr
method
regard
clinic
evalu
mlpa
method
provid
addit
result
specimen
due
comprehens
format
higher
test
sensit
capabl
detect
pathogen
compar
realaccur
respiratori
rt
pcr
kit
respiratori
tract
infect
common
infect
worldwid
estim
two
four
infect
per
year
adult
especi
colder
season
respiratori
tract
infect
occur
frequent
may
caus
signific
morbid
mortal
immunosuppress
popul
oncolog
patient
clinic
present
infect
respiratori
pathogen
rang
asymptomat
sever
diseas
consid
broad
rang
respiratori
pathogen
hardli
possibl
assign
clinic
symptom
distinct
etiolog
henc
molecular
diagnost
method
establish
gold
standard
replac
less
sensit
http
labori
tradit
diagnost
method
viru
isol
cultur
direct
immunofluoresc
howev
comprehens
investig
respiratori
tract
infect
timeand
resourceconsum
appli
singleplex
pcr
therefor
multiplexbas
test
method
detect
numer
respiratori
pathogen
enter
routin
diagnost
present
studi
broad
spectrum
multiplex
method
respifind
pathofind
maastricht
netherland
compar
routin
use
test
realaccur
respiratori
rt
pcr
kit
also
pathofind
analyz
respiratori
sampl
oncolog
patient
evalu
respifind
compris
three
major
part
verif
analyt
perform
routin
perform
comparison
rt
pcr
method
evalu
time
result
ttr
method
studi
approv
local
ethic
committe
current
use
method
detect
respiratori
pathogen
realaccur
respiratori
rt
pcr
kit
allow
differenti
respiratori
virus
influenzaviru
ab
infab
respiratori
syncyt
viru
b
rsv
ab
parainfluenzaviru
coronaviru
rhinoenteroviru
rhventero
human
metapneumoviru
hmpv
adenoviru
adv
principl
test
onestep
revers
transcript
subsequ
amplif
detect
via
taqman
probe
lightcycl
platform
requir
separ
master
mix
pathogen
henc
analysi
pathogen
singl
clinic
specimen
capillari
includ
control
necessari
refer
physician
possibl
order
individu
pathogen
well
whole
panel
new
method
respifind
avail
austria
sinc
decemb
allow
simultan
differenti
pathogen
panel
consist
virus
realaccur
respiratori
rt
pcr
kit
cover
addit
infa
bocaviru
four
bacteri
pathogen
chlamydophila
pneumonia
mycoplasma
pneumonia
legionella
pneumophila
bordetella
pertussi
principl
test
multiplex
ligationdepend
probe
amplif
mlpa
subsequ
revers
transcript
requir
two
lightcycl
capillari
per
specimen
prior
analysi
sampl
extract
qiaamp
minelut
viru
spin
kit
qiagen
hilden
germani
accord
instruct
use
specimen
input
volum
l
output
volum
l
method
sampl
store
c
prior
routin
diagnost
realaccur
respiratori
rt
pcr
kit
minim
possibl
effect
analyt
perform
thaw
extract
analysi
mlpa
method
clinic
sampl
discrep
result
retest
depart
virolog
medic
univers
vienna
singleplex
real
time
pcr
detect
via
taqman
probe
nest
pcr
employ
detect
rhinoviru
analyt
perform
respifind
verifi
test
accuraci
interand
intraassay
variabl
specif
sensit
base
establish
guidelin
known
posit
sampl
two
differ
extern
qualiti
assess
servic
qcmd
ukneqa
contain
adv
bordetella
pertussi
hmpv
infa
infb
rhinoviru
b
type
rsv
rsv
b
test
determin
accuraci
interand
intraassay
variabl
determin
repeatedli
analyz
sampl
posit
neg
sampl
test
specif
atcc
strain
streptococcu
pneumonia
haemophilu
influenza
staphylococcu
aureu
pseudomona
aeruginosa
klebsiella
pneumonia
spike
previous
neg
test
pharyng
wash
sampl
dilut
seri
hmpv
undilut
analyz
compar
sensit
retrospect
studi
mlpa
method
compar
realaccur
respiratori
rt
pcr
kit
test
respiratori
sampl
pharyng
wash
nasopharyng
swab
lower
respiratori
tract
sampl
oncolog
patient
treat
intern
depart
elisabethinen
hospit
linz
receiv
respiratori
season
novemb
april
routin
diagnost
realaccur
respiratori
rt
pcr
kit
origin
sampl
anonym
assign
continu
id
number
analysi
respifind
sampl
reextract
describ
section
ttr
method
evalu
also
elucid
econom
aspect
capabl
mlpa
method
compris
period
time
begin
analysi
sampl
includ
purif
nucleic
acid
final
result
ttr
consist
hand
time
hot
period
incub
determin
typic
run
three
sampl
measur
stopwatch
data
analyz
spss
version
use
descript
statist
conting
tabl
fisher
exact
test
p
valu
consid
signific
accuraci
ten
differ
pathogen
correctli
detect
accord
result
extern
qc
rel
standard
deviat
rsd
determin
interassay
variabl
rsd
intraassay
variabl
analyz
cross
pointvalu
specif
crossreact
seen
spike
common
respiratori
bacteria
neg
test
pharyng
wash
sampl
concern
sensit
respifind
abl
detect
higher
dilut
hmpv
equal
sensit
compar
realaccur
respiratori
rt
pcr
kit
result
summar
tabl
demograph
clinic
data
summar
tabl
tabl
respifind
yield
addit
posit
result
due
variou
factor
realaccur
respiratori
rt
pcr
kit
allow
select
individu
pathogen
refer
physician
studi
partial
panel
order
sampl
mostli
limit
diagnost
influenza
virus
analyz
sampl
respifind
addit
pathogen
detect
six
total
sampl
two
addit
rhinoenteroviru
infect
two
coronaviru
infect
one
hmpv
rsv
infect
success
confirm
refer
laboratori
except
one
rhventero
posit
sampl
upon
retest
realaccur
respiratori
rt
pcr
kit
pathogen
except
rhventero
detect
correctli
tabl
higher
test
sensit
respifind
also
shown
nine
addit
posit
result
rhventero
hmpv
order
found
routin
test
could
confirm
refer
laboratori
final
respifind
extend
spectrum
four
viral
four
bacteri
addit
pathogen
bocaviru
detect
seven
sampl
studi
collect
one
sampl
contain
could
confirm
refer
laboratori
tabl
use
routin
diagnost
respiratori
pathogen
detect
least
studi
period
patient
howev
use
comprehens
approach
respifind
result
achiev
significantli
higher
proport
patient
patient
p
fisher
exact
test
two
patient
group
exclud
analysi
unresolv
differ
test
time
sampl
patient
undergon
hematopoiet
stem
cell
transplant
hsct
median
day
hsct
day
three
patient
underw
condit
hsct
studi
period
respiratori
pathogen
detect
analysi
respifind
patient
receiv
hsct
wherea
patient
shortli
hsct
pathogen
detect
thu
patient
shortli
hsct
significantli
higher
burden
proven
viral
respiratori
tract
infect
patient
without
hsct
p
fisher
exact
test
first
time
requir
extract
nucleic
acid
analyz
typic
test
three
sampl
ttr
min
incub
min
hot
min
determin
rt
pcr
method
demand
purif
supplementari
neg
control
comparison
ttr
min
incub
min
hot
min
respifind
use
realaccur
respiratori
rt
pcr
kit
analysi
complet
respiratori
panel
three
clinic
sampl
correspond
neg
posit
control
requir
lightcycl
posit
lightcycl
carousel
l
capillari
hold
capillari
thu
two
run
need
test
three
sampl
due
possibl
use
two
lightcycl
parallel
period
incub
min
count
hot
min
process
three
sampl
result
total
ttr
min
analysi
use
respifind
two
vial
per
sampl
process
manual
transfer
preamplif
hybrid
pcr
melt
curv
analysi
analysi
three
specimen
took
hot
min
period
incub
min
total
ttr
parallel
analysi
three
sampl
min
min
period
incub
min
hot
realaccur
respiratori
rt
pcr
kit
min
min
period
incub
min
hot
respifind
fig
studi
evalu
new
commerci
avail
multiplex
format
molecular
biolog
diagnosi
respiratori
pathogen
respifind
comparison
routin
use
realaccur
respiratori
rt
pcr
kit
analyt
perform
respifind
fulfil
preset
criteria
note
mlpa
method
sensit
detect
rhventero
result
group
indic
analyt
sensit
respifind
rang
copi
per
reaction
target
use
commerci
avail
quantit
dnarna
pcr
control
equal
singleplex
pcr
sensit
howev
absolut
limit
detect
individu
target
avail
either
method
result
clinic
perform
reveal
higher
test
sensit
mlpa
test
principl
comparison
rt
pcr
method
posit
rate
rose
analyz
collect
besid
higher
test
sensit
extend
spectrum
respifind
contribut
higher
posit
rate
bocaviru
detect
sampl
reason
differ
posit
rate
select
order
routin
diagnosi
six
total
sampl
mlpa
method
detect
addit
pathogen
actual
includ
rang
realaccur
respiratori
rt
pcr
kit
order
result
five
sampl
confirm
refer
laboratori
retest
rt
pcr
method
yield
result
four
six
sampl
confirm
higher
test
sensit
respifind
rhventero
narrow
spectrum
diagnost
respiratori
tract
infect
consid
problemat
nonspecif
clinic
present
therefor
pcr
detect
infab
rsv
piv
second
line
hmpv
rhventero
cov
adv
recommend
atrisk
patient
especi
hsct
recipi
import
accur
swiftli
diagnos
respiratori
infect
potenti
progress
sever
complic
pneumonia
also
hospit
hygien
reason
accordingli
hsct
recipi
sampl
collect
significantli
higher
burden
respiratori
tract
infect
oncolog
patient
similar
studi
hsct
recipi
lower
number
posit
case
report
seven
viral
pathogen
infa
b
piv
hmpv
target
brittainlong
et
al
use
multiplex
realtim
pcr
similar
spectrum
pathogen
respifind
patient
collect
underli
diseas
report
posit
rate
sampl
infa
commonest
pathogen
follow
rhv
compar
result
mlpa
method
extend
pathogen
spectrum
compar
rt
pcr
method
studi
detect
two
viral
pathogen
spectrum
bocaviru
two
sampl
one
patient
five
sampl
four
differ
patient
role
human
bocaviru
respiratori
tract
infect
yet
fulli
understood
pathogen
potenti
attribut
infect
high
viral
load
function
helper
viru
may
trigger
replic
anoth
respiratori
viru
unlik
bocaviru
clear
clinic
relev
respiratori
tract
infect
report
milano
et
al
sampl
collect
hsct
recipi
studi
collect
coronaviru
detect
sampl
time
report
molecular
diagnost
test
respiratori
infect
import
correct
treatment
patient
adequ
hospit
hygien
measur
respifind
show
ttr
h
min
three
clinic
sampl
consist
h
indic
manufactur
sinc
ttr
consist
incub
time
manufactur
recent
introduc
updat
version
kit
reduct
incub
time
h
thu
report
result
within
work
day
h
easili
possibl
ttr
realaccur
respiratori
rt
pcr
kit
h
min
significantli
longer
ttr
h
state
manufactur
sinc
independ
number
patient
sampl
alreadi
lcrun
last
min
analyz
complet
respiratori
panel
three
sampl
parallel
two
lightcycl
need
one
machin
incub
time
doubl
receipt
result
delay
min
howev
real
time
pcr
instrument
avail
three
sampl
process
singl
run
multiplex
format
respifind
allow
analysi
patient
sampl
parallel
underscor
advantag
multiplexbas
method
comparison
singleplex
pcr
concern
factor
time
import
hand
time
hot
halv
mlpa
method
signific
improv
regard
lab
staff
time
commit
conclus
respifind
provid
reliabl
result
diagnosi
respiratori
pathogen
due
unmodifi
multiplex
format
test
broad
spectrum
pathogen
cover
everi
run
significantli
increas
posit
rate
examin
collect
realaccur
respiratori
rt
pcr
kit
furthermor
use
respifind
offer
signific
advantag
concern
hot
compar
rt
pcr
method
none
